APR-548
- Generic Name
- APR-548
- Drug Type
- Small Molecule
- Background
APR-548 is an analog of eprenetapopt and a reactivator of mutant p53.
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Aprea Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT04638309
- Locations
- 🇺🇸
Dana Farber Cancer Institue, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath